Retrieval of HCV patients lost to follow-up as a strategy for Hepatitis C Microelimination: results of a Brazilian multicentre study.
DAA treatment
Hepatitis C
Micro-elimination
Non-SVR
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
13 Jul 2023
13 Jul 2023
Historique:
received:
29
10
2022
accepted:
16
03
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
13
7
2023
Statut:
epublish
Résumé
Several HCV patients in Brazil were lost to follow-up (LTFU) in the last two decades before achievement of sustained virological response (SVR). Strategies to recall those diagnosed but untreated patients have been used elsewhere with different success rates. To identify and retrieve LTFU patients in order to offer them the treatment with the current highly effective direct acting antiviral agents (DAAs). Registries ofall HCV patients from three large reference centers in Brazil were retrospectively reviewed to identify those with no registry of SVR. Reasons for non-achievement of SVR were elicited in HCV-RNA + patients. All patients who were not treated or cured were contacted to offer the therapy with DAAs. 10,289 HCV patients (50% males, mean age 52 ± 11 years) were identified. Only 4,293 (41.7%) had been successfully treated previously. From the remaining 5,996 most were LTFU (59%), were not treated for other reasons (14.7%) or were non-responders (26.3%). After revision of the charts 3,559 were considered eligible to be retrieved. The callback success of phone calls was 18%, 13% to cellphone messages (SMS or WhatsApp) and 7% to regular mail. Five-hundred sixty patients had been already treatedor were on treatment and 234 were reported to be dead or transplanted. Finally, 201 had made an appointment and initiated antiviral treatment. Even considering the low callback rate, retrieval of LTFU patients was shown to be an important strategy forhepatitis C micro-elimination in Brazil.
Sections du résumé
BACKGROUND
BACKGROUND
Several HCV patients in Brazil were lost to follow-up (LTFU) in the last two decades before achievement of sustained virological response (SVR). Strategies to recall those diagnosed but untreated patients have been used elsewhere with different success rates.
AIM
OBJECTIVE
To identify and retrieve LTFU patients in order to offer them the treatment with the current highly effective direct acting antiviral agents (DAAs).
METHODS
METHODS
Registries ofall HCV patients from three large reference centers in Brazil were retrospectively reviewed to identify those with no registry of SVR. Reasons for non-achievement of SVR were elicited in HCV-RNA + patients. All patients who were not treated or cured were contacted to offer the therapy with DAAs.
RESULTS
RESULTS
10,289 HCV patients (50% males, mean age 52 ± 11 years) were identified. Only 4,293 (41.7%) had been successfully treated previously. From the remaining 5,996 most were LTFU (59%), were not treated for other reasons (14.7%) or were non-responders (26.3%). After revision of the charts 3,559 were considered eligible to be retrieved. The callback success of phone calls was 18%, 13% to cellphone messages (SMS or WhatsApp) and 7% to regular mail. Five-hundred sixty patients had been already treatedor were on treatment and 234 were reported to be dead or transplanted. Finally, 201 had made an appointment and initiated antiviral treatment.
CONCLUSION
CONCLUSIONS
Even considering the low callback rate, retrieval of LTFU patients was shown to be an important strategy forhepatitis C micro-elimination in Brazil.
Identifiants
pubmed: 37442976
doi: 10.1186/s12879-023-08169-0
pii: 10.1186/s12879-023-08169-0
pmc: PMC10339629
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
468Informations de copyright
© 2023. The Author(s).
Références
J Hepatol. 2022 Feb;76(2):470-472
pubmed: 34437907
Public Health Rep. 2016 May-Jun;131 Suppl 2:49-56
pubmed: 27168662
Hepatol Med Policy. 2018 Jan 31;3:5
pubmed: 30288328
Eur J Intern Med. 2022 Jul;101:93-97
pubmed: 35527178
J Viral Hepat. 2023 Jan;30(1):56-63
pubmed: 36197907
Liver Int. 2019 Mar;39(3):455-462
pubmed: 30204289
Ann Hepatol. 2019 Nov - Dec;18(6):849-854
pubmed: 31537509
Braz J Infect Dis. 2022 Jul-Aug;26(4):102388
pubmed: 35905930
Expert Opin Pharmacother. 2021 Sep;22(13):1729-1741
pubmed: 33896315
J Viral Hepat. 2022 Jul;29(7):579-583
pubmed: 35555847
EBioMedicine. 2016 Oct;12:189-195
pubmed: 27596150
BMC Gastroenterol. 2021 May 8;21(1):209
pubmed: 33964873
J Hepatol. 2021 Jan;74(1):31-36
pubmed: 32777322
Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415
pubmed: 35180382
Hepatology. 2002 Nov;36(5 Suppl 1):S237-44
pubmed: 12407599